In recent years, the development of immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitors and inhibitors of programmed cell death protein 1 or its ligand (PD1, PDL1), has considerably improved the survival of patients with certain advanced cancers (4). This evidence concerns the gene CTLA4 and cancer.